Eurofins Reinforces Its Footprint in Japan with the Acquisition of Nihon Soken
15 July 2015 - 3:30PM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in environment
testing services, announces that it has signed an agreement to
acquire Nihon Soken in Japan. The transaction is expected to close
by the end of July.
Founded in 1971, Nihon Soken is one of the country’s leading
environmental testing service providers with a strong focus in
pollution analysis, and is the largest laboratory serving the
Fukushima prefecture. Nihon Soken employs 112 staff, and expects to
generate revenues of almost EUR 10m in 2015, with EBITDA margin
broadly in-line with Eurofins’ objective.
The acquisition provides the Group market leadership in
radioactive surface measurement testing in Fukushima, and
reinforces Eurofins’ Radioactive Material Analysis (RMA)
capabilities in Japan. Nihon Soken should allow the Group to
further leverage its state-of-the-art high throughput laboratory
for RMA in Tokyo, as well as its global network of RMA laboratories
in China, France and Germany. In addition, Nihon Soken’s expertise
in remediation and monitoring is a strong addition to the Group’s
existing competencies.
Comment from Mr. Kazuyoshi Oishi, Nihon Soken President
and CEO: “It is a great honor to become part of the Eurofins global
group of companies. As one of the oldest environment testing
companies in Japan, Nihon Soken is committed to global environment
protection, and to further developing its competencies within the
Eurofins Group and its footprint in the region.”
Comment from Dr. Gilles Martin, Eurofins CEO: “Nihon
Soken is an excellent strategic fit to Eurofins’ existing
activities in Japan, and reinforces the Group’s growing presence in
the Asia Pacific region. Furthermore, this acquisition provides the
Group an opportunity to play a more active role in the country’s
remediation and long-term recovery efforts following the tragic
Fukushima nuclear accident in 2011, by leveraging Eurofins’ full
laboratory network capabilities.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 17,000 staff in more than 200 laboratories across 36
countries, Eurofins offers a portfolio of over 100,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150714006821/en/
Eurofins Scientific GroupInvestor Relations, +32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2023 to Sep 2024